Jiangsu Hansoh Pharmaceutical Group Company Limited

Overview

Jiangsu Hansoh Pharmaceutical Group Company Limited is a leading pharmaceutical company in China, specializing in the research, development, manufacturing, and marketing of a variety of drugs. The company focuses on therapeutic areas such as oncology, infectious diseases, and diabetes management.

Therapeutic areas

API / Drug Master Files

Jiangsu Hansoh Pharmaceutical Group Company Limited holds 18 active (23 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CARFILZOMIB, NON-STERILE, BULK DRUG SUBSTANCEActive2025-03-10
• HS-20098Active2024-09-05
• ENZALUTAMIDEActive2024-09-04
• PEMETREXED DISODIUM USP NON-STERILEActive2022-06-15
• DEGARELIX ACETATE NON-STERILE BULK DRUG SUBSTANCEActive2022-01-27
• MICAFUNGIN SODIUMActive2022-01-20
• NINTEDANIB ESYLATE, NON-STERILE, BULK DRUG SUBSTANCEActive2019-12-20
• FULVESTRANT USP, NON-STERILE BULK DRUG SUBSTANCEActive2019-09-05
• MICAFUNGIN SODIUMActive2018-12-14
• AZACITIDINE, NON-STERILE BULK DRUG SUBSTANCEActive2018-09-21
• DECITABINE, NON-STERILE BULK DRUG SUBSTANCEActive2018-05-21
• BORTEZOMIBActive2018-01-19
• DAPAGLIFLOZINActive2017-11-21
• VINORELBINE TARTRATE, USPActive2017-04-13
• GEMCITABINE HYDROCHLORIDE USPActive2017-03-24

Showing 15 of 23 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Jiangsu Hansoh Pharmaceutical Group Company Limited in our records. PharmaTek screens the full directory against live FDA enforcement data.